Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Studying the Humoral Response against SARS-CoV-2 in Cuban COVID-19 Recovered Patients.
Orosa Vázquez I, Díaz M, Zúñiga Rosales Y, Amada K, Chang J, Relova Hernández E, Tundidor Y, Roblejo Balbuena H, Monzón G, Torres Rives B, Noa Romero E, Carrillo Valdés D, Valdivia Álvarez I, Delahanty Fernández A, Díaz C, Solozabal J, Gil M, Sánchez B, Rojas G, Marcheco B, Carmenate T. Orosa Vázquez I, et al. Among authors: noa romero e. J Immunol Res. 2024 Sep 25;2024:7112940. doi: 10.1155/2024/7112940. eCollection 2024. J Immunol Res. 2024. PMID: 39359695 Free PMC article.
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.
Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C, Sánchez-Ramírez B, Perez-Nicado R, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, García-García MLÁ, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Rodríguez-Prieto LD, Puga-Gómez R, Guerra-Chaviano PP, Zúñiga-Rosales Y, Marcheco-Teruel B, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Porto-González D, Fernández-Medina O, Valdés-Zayas A, Chen GW, Herrera-Martínez L, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Chang-Monteagudo A, et al. Among authors: noa romero e. Lancet Reg Health Am. 2021 Dec;4:100079. doi: 10.1016/j.lana.2021.100079. Epub 2021 Sep 15. Lancet Reg Health Am. 2021. PMID: 34541571 Free PMC article.
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Ángeles García-García M, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, Calcagno A, Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Ochoa-Azze R, et al. Among authors: noa romero e. Lancet Respir Med. 2022 Aug;10(8):785-795. doi: 10.1016/S2213-2600(22)00100-X. Epub 2022 Jun 9. Lancet Respir Med. 2022. PMID: 35691295 Free PMC article. Clinical Trial.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Eugenia-Toledo-Romaní M, Verdecia-Sánchez L, Rodríguez-González M, Rodríguez-Noda L, Valenzuela-Silva C, Paredes-Moreno B, Sánchez-Ramírez B, Pérez-Nicado R, González-Mugica R, Hernández-García T, Bergado-Baez G, Pi-Estopiñán F, Cruz-Sui O, Fraga-Quintero A, García-Montero M, Palenzuela-Díaz A, Baró-Román G, Mendoza-Hernández I, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, Ramírez Gonzalez U, García-Vega Y, Pérez-Massón B, Guang-Wu-Chen, Boggiano-Ayo T, Ojito-Magaz E, Rivera DG, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group; Gómez-Maceo Y, Reyes-Matienzo R, Manuel Coviella-Artime J, Morffi-Cinta I, Martínez-Pérez M, Castillo-Quintana I, Garcés-Hechavarría A, Valera-Fernández R, Martínez-Bedoya D, Garrido-Arteaga R, Cardoso-SanJorge F, Quintero Moreno L, Ontivero-Pino I, Teresa Pérez-Guevara M, Morales-García M, Noa-Romero E, Orosa-Vázquez I, Díaz-Hernández M, Rojas G, Tundidor Y, García-López E, Muñoz-Morejon Y, Galano-Frutos E, Rodríguez-Alvarez J, Arteaga A, Medina Nápoles M, Espi Ávila J, Fontanies Fernández M. Eugenia-Toledo-Romaní M, et al. Among authors: noa romero e. Vaccine. 2022 Jul 29;40(31):4220-4230. doi: 10.1016/j.vaccine.2022.05.082. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35691871 Free PMC article. Clinical Trial.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C, Paredes-Moreno B, Sanchez-Ramirez B, González-Mugica R, Hernández-Garcia T, Orosa-Vázquez I, Díaz-Hernández M, Pérez-Guevara MT, Enriquez-Puertas J, Noa-Romero E, Palenzuela-Diaz A, Baro-Roman G, Mendoza-Hernández I, Muñoz Y, Gómez-Maceo Y, Santos-Vega BL, Fernandez-Castillo S, Climent-Ruiz Y, Rodríguez-Noda L, Santana-Mederos D, García-Vega Y, Chen GW, Doroud D, Biglari A, Boggiano-Ayo T, Valdés-Balbín Y, Rivera DG, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Toledo-Romani ME, et al. Among authors: noa romero e. Med. 2022 Nov 11;3(11):760-773.e5. doi: 10.1016/j.medj.2022.08.001. Epub 2022 Aug 8. Med. 2022. PMID: 35998623 Free PMC article. Clinical Trial.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, Pérez NP, Paredes-Moreno B, Rodríguez-González M, Valenzuela-Silva C, Sánchez-Ramírez B, Rodríguez-Noda L, Pérez-Nicado R, González-Mugica R, Hernández-García T, Fundora-Barrios T, Echevarría MD, Enriquez-Puertas JM, Infante-Hernández Y, Palenzuela-Díaz A, Gato-Orozco E, Chappi-Estévez Y, Francisco-Pérez JC, Suarez-Martinez M, Castillo-Quintana IC, Fernandez-Castillo S, Climent-Ruiz Y, Santana-Mederos D, García-Vega Y, Toledo-Romani ME, Doroud D, Biglari A, Valdés-Balbín Y, García-Rivera D, Vérez-Bencomo V; SOBERANA Research Group. Puga-Gómez R, et al. Int J Infect Dis. 2023 Jan;126:164-173. doi: 10.1016/j.ijid.2022.11.016. Epub 2022 Nov 18. Int J Infect Dis. 2023. PMID: 36403819 Free PMC article. Clinical Trial.
Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.
Bermúdez-Abreut E, Fundora-Barrios T, Hernández Fernández DR, Noa Romero E, Fraga-Quintero A, Casadesús Pazos AV, Fernández-Marrero B, Plasencia Iglesias CA, Clavel Pérez M, Sosa Aguiar K, Sánchez-Ramírez B, Hernández T. Bermúdez-Abreut E, et al. Among authors: noa romero e. PLoS One. 2025 Jan 3;20(1):e0312402. doi: 10.1371/journal.pone.0312402. eCollection 2025. PLoS One. 2025. PMID: 39752453 Free PMC article.
Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE).
Hernández-Bernal F, Noa-Romero E, Quintana-Guerra J, Chávez-Chong CO, Martín-Bauta Y, Alvaré-Alvaré L, Salvato-Dueñas A, Felipe-Mallea D, Porta-Díaz M, Cruz-Sui O, Urrutia-Pérez K, Urrutia-Pérez K, Rodríguez-Reinoso JL, Alonso-Valdés M, Cinza-Estévez Z, Rodríguez-Triana A, Cruz-Gómez Y, Limonta-Fernández M, Rodríguez-Acosta M, Ayala-Ávila M, Muzio-González VL; ABDALA Group of Investigators. Hernández-Bernal F, et al. Among authors: noa romero e. Vaccine. 2024 Sep 17;42(22):126223. doi: 10.1016/j.vaccine.2024.126223. Epub 2024 Aug 15. Vaccine. 2024. PMID: 39151232 Free article. Clinical Trial.
Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3-18 years old.
García-Rivera D, Puga-Gómez R, Fernández-Castillo S, Paredes-Moreno B, Ricardo-Delgado Y, Rodríguez-González M, Silva CV, Pérez-Nicado R, Rodríguez-Noda L, Santana-Mederos D, Climent-Ruiz Y, Noa-Romero E, Cruz-Sui O, Sánchez-Ramírez B, Hernández-García T, Palenzuela-Diaz A, Martínez-Perez M, García-López A, Valdés-Balbín Y, Vérez-Bencomo VG. García-Rivera D, et al. Among authors: noa romero e. Vaccine X. 2024 Dec 6;22:100595. doi: 10.1016/j.jvacx.2024.100595. eCollection 2025 Jan. Vaccine X. 2024. PMID: 39737224 Free PMC article.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, Del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, Del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. Hernández-Bernal F, et al. Among authors: noa romero e. EClinicalMedicine. 2022 Apr;46:101383. doi: 10.1016/j.eclinm.2022.101383. Epub 2022 Apr 9. EClinicalMedicine. 2022. PMID: 35434578 Free PMC article.
16 results